Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TUG1 ASO
- Development stage
- Unknown
- Lead developer
- NANO mRNA
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
TUG1 ASO is an antisense oligonucleotide (ASO) therapeutic being developed by NANO mRNA for the treatment of glioblastoma multiforme (GBM). The drug targets taurine upregulated gene 1 (TUG1), a long non-coding RNA (lncRNA) that is significantly upregulated in GBM and plays a critical role in tumor cell proliferation, survival, and resistance to standard therapies like temozolomide. By binding to the TUG1 transcript, the ASO triggers its degradation, thereby suppressing the oncogenic activity of the lncRNA. TUG1 ASO is currently in Phase 1 clinical development, representing a novel approach to treating aggressive brain tumors by modulating non-coding RNA expression.
- Other names
- taurine upregulated gene 1 antisense oligonucleotideTUG1-ASOTUG-1-ASOTUG 1-ASO
02
Targets
TUG1
Beyond the preview
Go deeper on TUG1 ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TUG1 ASO.